Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is ad 1) to measure the depth of hypnosis as assessed by BIS and cAAI during an average general anesthesia with xenon or sevoflurane and to establish a reliable monitoring system for measuring and documenting the actual depth of hypnosis for the volatile anesthetics investigated. Ad 2) the question is to be answered whether 4 mg dexamethasone i.v. is an effective prophylactic treatment against postoperative nausea and vomiting in case of xenon or sevoflurane anesthesia. Ad 3) it serves to gain evidence about the (non-)effectiveness and kinetics of ondansetron as antiemetic remedy after xenon or sevoflurane anesthesia.


Clinical Trial Description

1. Patients included into the trial will randomly be allocated to either 0.8-1.1 minimum alveolar concentration (MAC) xenon in 30 % oxygen or 0.8-1.1 MAC sevoflurane (age adapted)/30 % oxygen. The MAC is defined and will therefore be applied according to the investigated subject`s age. Premedication will be performed with midazolam 7.5 mg orally 45 min before induction (standard dose and application form for adults as clinical practice of our department). Anesthesia will be induced in both groups with propofol 2 mg/kg i.v. and remifentanil 0.5 mcg/kg/min by infusion over 60 s. For tracheal intubation non-depolarizing neuromuscular blocking agents can be used (rocuronium 0.6 mg/kg). Both groups will receive remifentanil at a base rate of 0.2 mcg/kg/min. Xenon or sevoflurane can be titrated in the range from 0.8-1.1 MAC according to clinical needs based on the patient's hemodynamic, autonomic and somatic signs. Twenty minutes before the estimated cessation of all surgical procedures 0.05 mg kg-1 piritramide for post anesthetic pain management will be administered intravenously, as well as a short infusion of metamizole 15 mg kg-1.

Depth of anesthesia (hypnosis) will be monitored with spontaneous EEG (BIS VISTA, Aspect Medical Systems, Newton, MA) and the mid latency auditory evoked potentials including a monitoring variable indicating the patients hypnotic state calculated from the MLAEP and the electroencephalogram, the composite A-Line ARX Index (cAAI) with the AEP Monitor/2 (Danmeter A/S, Odense, Denmark). Dosing will be conducted according to the current clinical standard without the monitoring, thus the anesthesia provider will be blinded towards both measurements.

2. After induction of anesthesia patients will be randomized to a second factor, i.e. 4 mg dexamethasone or placebo for the prevention of PONV. To avoid potential imbalances, this will be achieved using a factorial design. The application of dexamethasone or placebo will be blinded to the investigator assessing postoperative nausea and vomiting.

3. Patients who experience significant nausea will be randomized to receive either 4 mg ondansetron or placebo and the course of nausea will be assessed for > 32 min. Again, the application of ondansetron or placebo will be blinded to the investigator assessing postoperative nausea and vomiting. If the symptoms of postoperative nausea and vomiting persist for more than 32 min after treatment additional rescue treatment will be offered. Of note, all patients are able to receive further rescue treatment at any time point of the study on demand. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00793663
Study type Interventional
Source RWTH Aachen University
Contact
Status Completed
Phase Phase 4
Start date November 2008
Completion date April 2011

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03639012 - Outcomes of Carbohydrate Loading Paediatric Patients Preoperatively for Tonsillectomy and Adenoidectomy N/A
Not yet recruiting NCT01389570 - Postoperative Nausea/Vomiting and Acupressure Phase 2
Completed NCT00830089 - Trial of a Transversus Abdominis Plane (TAP) Block in Laparoscopic Colorectal Surgery N/A
Terminated NCT05112575 - Evaluation of Patient Stress Level Caused by Radiological Investigations in Early Postoperative Phase After Craniotomy
Completed NCT04759079 - The Effects of Acupuncture Against Postoperative Nausea and Vomit After Laparoscopic Cholecystectomy N/A
Active, not recruiting NCT03712891 - Evaluation of Providing Coffee to Patients Postoperatively to Decrease Length of Stay in the PACU N/A
Completed NCT01834898 - Safety and Tolerability of Controlled-release Oxycodone on Postoperative Pain in Oncologic Head and Neck Surgery N/A
Completed NCT03631004 - Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients Phase 2/Phase 3
Completed NCT05618236 - Sugammadex and Neostigmine in Pediatric Patients
Not yet recruiting NCT05632224 - Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery Phase 4
Completed NCT01020903 - Aprepitant for Post-operative Nausea N/A
Completed NCT03503292 - Pharmacogenomics and Post-Operative Nausea and Vomiting Phase 4
Completed NCT05841693 - Quality of Recovery in Parturients Consumed Preoperative Carbohydrate Fluid for Elective Cesarean Delivery Phase 4
Completed NCT04742660 - The Effect of Glycyrrhizin on the Occurrence of Postoperative Nausea and Vomiting N/A
Completed NCT03100669 - Implementing a Postoperative MIRP (Minimally Invasive Repair of Pectus) Program Via Tele-monitoring
Terminated NCT02765750 - Postoperative Outcomes After Positive Intraoperative Messages N/A
Terminated NCT01798316 - IV Acetaminophen for Postoperative Analgesia Phase 4
Completed NCT03387956 - Intrathecal Atropine to Prevent Postoperative Nausea and Vomiting N/A
Completed NCT04718727 - Olanzapine for the Prevention of Postoperative Nausea and Vomiting Phase 1/Phase 2
Recruiting NCT06423456 - Postoperative Pain Control Following Hysteroscopy N/A